Xeris Biopharma logo
Xeris Biopharma
XERS | NASDAQ
Chart Builder DCF Calculator
$16.70
+$0.04 (+0.24%)
At close: Nov 16, 2026, 4:00 PM ET
$16.49
-$0.21 (-1.26%)
After-hours: Nov 16, 2026, 7:30 PM ET

Xeris Biopharma Company Profile

Company profile explained

Company Profile

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

Key Executives

Name Position
John Shannon Chairman & CEO
Beth Hecht Chief Legal Officer & Corporate Secretary
Kevin McCulloch President & Chief Operating Officer
Steven Pieper Chief Financial Officer
Allison Wey Senior Vice President of Investor Relations & Corporate Communications
Anh Nguyen Chief Medical Officer
Brian Conner SVP of Quality and Chief Compliance & Risk Officer
Joshua Bennett Vice President of Strategy & Business Development
Kendal Korte Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 14, 2026 8-K Current Report
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 09, 2026 8-K Current Report
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
View All SEC Filings ➞
Xeris Biopharma
Xeris Biopharma logo
Country United States
IPO Date Jun 21, 2018
Industry Biotechnology
Sector Healthcare
Employees 435
CEO John Shannon

Contact Details

1375 West Fulton Street Chicago, Illinois 60607 United States

Stock Details

Ticker Symbol XERS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001867096
CUSIP Number 98422E103
ISIN Number US98422E1038
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.